Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Essential Bee Venom (eBV), also known as Sweet Bee Venom, is a purified preparation of bee venom (apitoxin) used in Korean medicine for pharmacopuncture, which involves injecting medicinal substances at acupuncture points. [1, 21] It is specifically processed to remove major allergenic components, such as the enzyme phospholipase A2 (PLA2) and histamine, while aiming to retain therapeutically active peptides like melittin. [3, 24] This purification process is designed to reduce local allergic reactions like pain, swelling, and itching that are common with standard bee venom injections, while maintaining the anti-inflammatory and analgesic effects. [3, 24] eBV is primarily used to treat musculoskeletal and inflammatory conditions. [21] A clinical trial (NCT02364349) directly compared the local allergic responses of eBV and standard bee venom, confirming that eBV produced significantly fewer local reactions. [24]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on essential bee venom.